This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

30 May 2011

SEP & SCM Sign Manufacturing Agreement for Cancer Drug

Speciality European Pharma will transfer the commercial supply of its oncology product Plenaxis to UK contract manufacturing organisation SCM Pharma.

Speciality European Pharma (SEP) and SCM Pharma have inked a contract for the development and validation of the manufacturing and product testing processes at SCM’s UK-based facility.


SEP initiated the transfer of the commercial supply of its oncology product Plenaxis to SCM Pharma. Once the development is complete, SCM is expected to be the exclusive production partner for the vial filling of SEP’s hormonal product for the treatment of advanced and metastatic prostate cancer. SCM will then supply the licensed product in Germany and across Europe.


The product is a highly potent dry powder substance that will be filled in a highly contained environment and presented in terminally sterilized vial.

Related News